Close Menu


Based on the three-year overall survival and PFS rate, Bristol Myers Squibb intends to seek FDA approval for the combination in first-line, PD-L1 positive, NSCLC patients.

A roundup of some of the precision oncology-focused research presented at the Gastrointestinal Cancer Symposium in San Francisco, Jan. 23 to 25.

Researchers have identified immune cell gene expression signatures that could one day be developed into tests to predict response to treatment.

Gritstone Oncology's neoantigen-based immunotherapies for precision and off-the-shelf cancer treatment show promise in early safety trials.

The collaboration will test the effects of using human microbiome-derived bacteria alongside immune checkpoint inhibitor nivolumab to treat advanced metastatic cancers.

Researchers tested the combined treatment in mice, after detecting increased PAK4 expression and reduced immune infiltration in melanoma patients with poor anti-PD-1 response.

The results are of interest to drugmakers looking for scalable technology solutions for assessment of PD-L1 for predicting immunotherapy response.

Researchers have shown that the use of antibiotics in the weeks leading up to immunotherapy may lessen a patients' response to the treatment.

A collection of biomarker- and genomic testing-driven precision oncology research presented at the European Society of Medical Oncology Congress.

The study failed to show Opdivo plus chemoradiation significantly improves PFS compared to standard of care in MGMT-methylated glioblastoma.